Skip to Main content Skip to Navigation
Journal articles

Therapeutic antibodies for the treatment of pancreatic cancer.: Mabs against pancreatic cancer

Patrick Chames 1, * Brigitte Kerfelec 1 Daniel Baty 1 
* Corresponding author
Abstract : Pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower than 5%. In the U.S., this disease is the fourth leading cause of death and represents 6% of all cancer-related deaths. Gemcitabine, the current standard first-line treatment, offers marginal benefits to patients in terms of symptom control and prolongation of life. Since 1996, about 20 randomized phase III trials have been performed to improve the efficacy of gemcitabine, with little success regarding a significant improvement in survival outcomes. The need for novel therapeutic strategies, such as target therapy, is obvious. Monoclonal antibodies have finally come of age as therapeutics and several molecules are now approved for cancer therapies. This review aims to give a general view on the clinical results obtained so far by antibodies for the treatment of pancreatic cancer and describes the most promising avenues toward a significant improvement in the treatment of this frustrating disease.
Document type :
Journal articles
Complete list of metadata

Cited literature [50 references]  Display  Hide  Download
Contributor : Patrick Chames Connect in order to contact the contributor
Submitted on : Tuesday, July 6, 2010 - 10:28:28 AM
Last modification on : Tuesday, October 20, 2020 - 3:10:17 AM
Long-term archiving on: : Thursday, October 7, 2010 - 12:19:51 PM


Files produced by the author(s)




Patrick Chames, Brigitte Kerfelec, Daniel Baty. Therapeutic antibodies for the treatment of pancreatic cancer.: Mabs against pancreatic cancer. TheScientificWorldJournal, TheScientificWorld, 2010, 10, pp.1107-20. ⟨10.1100/tsw.2010.103⟩. ⟨inserm-00497886⟩



Record views


Files downloads